Not Tagged
Intercept Pharmaceuticals
[]
 presenting new safety and efficacy analysis from the regerate trial of oca for nash at #ddw2023 - over time elevated ldl reaches baseline (slide presenting to 54 months out). 
We raise awareness about the risks, causes and complications of fatty liver disease, and help those already diagnosed with NAFLD and NASH advocate for care.